Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

http://www.wikidata.org/entity/Q34295696

about

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group The Evolution of Therapies in Non-Small Cell Lung Cancer Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough Predictive biomarkers in precision medicine and drug development against lung cancer Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer The minority report: targeting the rare oncogenes in NSCLC Targeted therapies in development for non-small cell lung cancer Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1 Molecular pathology of non-small cell lung cancer: a practical guide.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Crizotinib in ROS1-rearranged non-small-cell lung cancer.Testing for ROS1 in non-small cell lung cancer: a review with recommendations Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing Beyond histology: translating tumor genotypes into clinically effective targeted therapies.PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.Molecular pathways: ROS1 fusion proteins in cancer.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report.Activation of RAS family members confers resistance to ROS1 targeting drugs.Mouse model for ROS1-rearranged lung cancer Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial Lung cancer molecular epidemiology in China: recent trends The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts.Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme

P2860

Q26780457-CE9A50BA-A71D-4FDD-8B1C-8E809A6CE190 Q26786932-6102BEDA-F7EF-4FB4-81D8-D2F612D10319 Q26799467-FD9953D7-9777-4B5C-B4C2-1F0C43C5F366 Q26824536-808648B5-029D-4A2A-A6A0-57AA6AA7F79B Q26851421-64471A2B-9AF2-45A2-8233-A7E09D6767D3 Q26851636-22C45012-541C-419E-B209-ACDFF9EF5024 Q27022852-484C0341-1EE8-43D5-BC43-FE7C8F4936E0 Q27025970-CC8F03BC-7A6E-4F12-8815-BDAF7CEA0DE5 Q27311389-B5F13982-0366-404C-BD84-3E74BD7DFDF3 Q27678436-D23C02F7-EAB5-4F30-B1F9-DDBA06BC0C73 Q27690919-5822432E-4581-4DF3-8A1E-CE86D38AF3AE Q27852601-50622D55-267D-42AD-855C-92826A86C331 Q27852699-0FCA7BC9-918A-4914-8840-852C723D2035 Q27853075-056F58B1-3E22-4E37-B6F0-722DCB4F5EA2 Q28070062-A4ED7214-7F60-4C7A-A9D6-4BC4FB524C99 Q28083446-815D2102-3F03-4D9F-AD56-D64AE4FE54B5 Q28385559-F4E3B19B-1581-4547-86BB-1063085B7541 Q28540825-7330BEA8-DD29-4999-8D78-1812E0D05450 Q30489158-143F9051-A2EE-46CA-8DA8-D72E0315D3E8 Q33560928-6C15C78A-C180-4B1C-BCA8-167C3273BDBC Q33688849-E31F6C87-05E4-45DE-90FA-C2023D800E19 Q33911863-54C1F529-B162-474B-BC69-61F3D587C961 Q34145016-4E4A22E7-1CAC-4AA8-A4A1-F65CE2FF527A Q34158153-BF0514A4-4611-407A-BA59-D8362642B1DB Q34159334-9C7A8FCC-7973-4623-8245-3CF032096CAD Q34347504-BEE6C06C-E17A-42E8-B9E0-351CE725345F Q34388696-DEBA2CD0-78F1-4902-8285-C9F6B3AA31B8 Q34392733-FE0B4F30-D8AD-4A0B-92AF-197B029B454A Q34427284-D4AABB64-B3EE-410D-8FBF-432ED21626BE Q34463388-30619D98-D7B2-4919-837D-A156BD46ABF3 Q34589721-BE48CDE6-C807-4CF9-BCED-A324ABF2DB3A Q34688871-D5375DFA-864E-4135-8F9F-869DDB846709 Q34871953-0F4081B4-F58D-4B60-942E-97C7E905769E Q35136424-C4D770A3-1B52-4AE2-8676-47F356079DCA Q35151926-57080588-456D-4A1A-9B0A-F2CA0F64BBF5 Q35168763-557189FE-AAF8-44AC-9695-1A458540A861 Q35200702-D8D0436F-6B89-4806-A973-F0473D74C3B3 Q35532823-D6BC3684-5889-4502-85CB-8BF2B4606313 Q35541769-F9A203CE-2DB7-48B8-BF87-22C851F7131B Q35772397-404FF710-8A71-4A6D-8116-BE4710119CB1

P2860

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

http://www.wikidata.org/entity/Q34295696

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@ast

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@en

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@nl

type

label

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@ast

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@en

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@nl

prefLabel

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@ast

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@en

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@nl

P1433

Q34295696-704F161A-C454-4067-B2F9-7129AEC0A187

P1476

Q34295696-1B56CD4C-7E60-4972-AE44-9E1706D2C760

P2093

Q34295696-11F9F51C-917F-4CA3-A71A-151A82E326AA

Q34295696-14C07554-214B-4CD6-8B59-0CAB799D9811

Q34295696-24B19999-6A44-44BA-8B9F-6F3AE466270F

Q34295696-455CBCDB-DF61-4E02-B055-E1AA2B4FD044

Q34295696-74B07EE4-390F-45E3-8C98-668DE9969F20

Q34295696-8879766A-FF94-468C-8554-85DA4EB60B02

Q34295696-88F64BA2-432A-4B28-9BC9-37B475552712

Q34295696-A2FEEF52-09DC-4FCE-B000-229B2E73C4F1

Q34295696-B063AD30-46F8-455A-96DC-A10524BF0E7F

Q34295696-BE110D8B-8B18-4AE9-B721-2EA515536B98

P2860

Q34295696-02BCE5EC-4C6C-44EF-9F5E-3BDF2C105570

Q34295696-095A441C-1870-43BA-9509-EF2BDEFFE42D

Q34295696-0A0476F3-F3E7-4771-8728-C3558A9428B4

Q34295696-15909E06-FC02-4AE9-A827-B4C479B394E5

Q34295696-16E8769A-E60B-4911-8EE3-0980B72DBB48

Q34295696-1AEE16DC-2E9F-4F3C-B96D-980CB8FBAFDB

Q34295696-27641E0C-6169-424A-89F4-B6329C200919

Q34295696-36C226F7-2EEF-4AC9-A378-34BF09ABC917

Q34295696-490B3248-E7C3-4CA8-B1C4-816B7B41B602

Q34295696-4EB4E862-997A-48EC-B6F4-6636B92E5F51

P304

Q34295696-2519F164-E438-474B-9D6E-0CD0FC06D54E

P31

Q34295696-B622BCF1-6606-4FF5-AA57-697D6C915AC9

P356

Q34295696-AC121B6D-B5B5-458C-8378-FF46D86313EF

P407

Q34295696-EBFA1972-B6DE-449D-9FDD-F04824F6E07C

P433

Q34295696-5F0754AE-011D-4869-B746-26F29CEE6FA3

P478

Q34295696-92E2A551-D0F7-4990-B615-C1AE329AF033

P577

Q34295696-7EB66E02-52AD-4A93-93FB-8655B9E2F141

P698

Q34295696-F257AB87-1D42-46AA-83A9-604EA2AD1316

P932

Q34295696-7E57DC37-C4A1-49B2-9215-27F5F0270B8E

P356

1078-0432.CCR-12-0550

P1433

Clinical Cancer Research

P1476

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

@en

P2093

Anh T Le

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Dara L Aisner

http://www.w3.org/2001/XMLSchema#string

Eamon M Berge

http://www.w3.org/2001/XMLSchema#string

Federico Cappuzzo

http://www.w3.org/2001/XMLSchema#string

Kurtis D Davies

http://www.w3.org/2001/XMLSchema#string

Luigi M Terracciano

http://www.w3.org/2001/XMLSchema#string

Marco Alloisio

http://www.w3.org/2001/XMLSchema#string

Margaret C Skokan

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice

Characterization of an activated human ros gene

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma

Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule

Expression and rearrangement of the ROS1 gene in human glioblastoma cells

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

P304

4570-4579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-0550

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22919003

http://www.w3.org/2001/XMLSchema#string

P932

3703205

http://www.w3.org/2001/XMLSchema#string